ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up – Time to Buy?

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) gapped up before the market opened on Monday . The stock had previously closed at $76.28, but opened at $82.30. ANI Pharmaceuticals shares last traded at $84.8250, with a volume of 115,338 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Guggenheim lifted their price target on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Barclays began coverage on ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. HC Wainwright upped their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

ANI Pharmaceuticals Stock Performance

The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $1.89 billion, a P/E ratio of 51.59 and a beta of 0.51. The business’s 50 day simple moving average is $82.81 and its two-hundred day simple moving average is $83.29.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The firm had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business’s revenue for the quarter was up 53.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $82.32, for a total transaction of $32,928.00. Following the sale, the vice president directly owned 74,874 shares of the company’s stock, valued at $6,163,627.68. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of ANI Pharmaceuticals stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. The trade was a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 27,601 shares of company stock worth $2,410,898. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its holdings in ANI Pharmaceuticals by 321.0% in the fourth quarter. SG Americas Securities LLC now owns 96,181 shares of the specialty pharmaceutical company’s stock worth $7,593,000 after purchasing an additional 73,334 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of ANI Pharmaceuticals by 93.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 89,777 shares of the specialty pharmaceutical company’s stock valued at $7,087,000 after buying an additional 43,449 shares during the period. Oliver Luxxe Assets LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter worth $1,823,000. Tudor Investment Corp ET AL purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth $1,085,000. Finally, Penn Capital Management Company LLC grew its holdings in shares of ANI Pharmaceuticals by 6.5% in the third quarter. Penn Capital Management Company LLC now owns 6,364 shares of the specialty pharmaceutical company’s stock worth $583,000 after acquiring an additional 387 shares during the period. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.